The Role of Oxygen Sensors, Hydroxylases, and HIF in Cardiac Function and Disease

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Townley Tilson, W H Davin ^a   Pi, Xinchun ^a   Xie, Liang ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLOGY; DISEASES; HEART; OXYGEN SENSORS; PHYSIOLOGICAL MODELS; PROTEINS; SUBSTRATES;

CARDIAC FUNCTIONS; CARDIAC TISSUES; CRITICAL COMPONENT; ISCHEMIC HEART DISEASE; PHYSIOLOGICAL RESPONSE; POST-TRANSLATIONAL MODIFICATIONS; REPERFUSION INJURY; THERAPEUTIC TARGETS;

OXYGEN;

2 OXOGLUTARIC ACID; ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; ERYTHROPOIETIN; FLAVINE ADENINE NUCLEOTIDE; HYDROGEN PEROXIDE; HYPOXIA INDUCIBLE FACTOR; I KAPPA B; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN; OXYGENASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROSTAGLANDIN SYNTHASE; PROSTANOID; PYRUVATE KINASE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; TRANSFORMING GROWTH FACTOR BETA; VON HIPPEL LINDAU PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MIXED FUNCTION OXIDASE;

ARTICLE; ATHEROSCLEROSIS; CALCIUM SIGNALING; HEART ARRHYTHMIA; HEART DISEASE; HEART FUNCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HUMAN; HYDROXYLATION; ISCHEMIC PRECONDITIONING; NONHUMAN; OXYGEN CONCENTRATION; OXYGEN SENSING; PROTEIN EXPRESSION; PROTEIN PROCESSING; VASCULAR REMODELING; CARDIAC MUSCLE; HEART; METABOLISM; PATHOLOGY; PHYSIOLOGY;

HEART; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MIXED FUNCTION OXYGENASES; MYOCARDIAL ISCHEMIA; MYOCARDIUM; OXYGEN;

EID: 84944246726     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/676893     Document Type: Article

References (137)

1. World Health Organization, The Top 10 Causes of Death, World Health Organization, Geneva, Switzerland, 2014, http: //www . who. int/mediacentre/factsheets/fs310/en/.
2. University TJH, ConditionsWe Treat: Coronary Artery Disease (Ischemic Heart Disease).
3. A. S. Go, D. Mozaffarian, V. L. Roger et al. , "Heart disease and stroke statistics-2013 update: A report from the American Heart Association," Circulation, vol. 127, no. 1,pp. e6-e245, 2013.
4. M. H. Soonpaa and L. J. Field, "Assessment of cardiomyocyte DNA synthesis in normal and injured adult mouse hearts," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 272, no. 1, pp. H220-H226, 1997.
5. P. Anversa and J. Kajstura, "Ventricularmyocytes are not terminally differentiated in the adult mammalian heart," Circulation Research, vol. 83, no. 1, pp. 1-14, 1998.
6. D. F. Wilson and M. Erecínska, "The oxygen dependence of cellular energy metabolism," Advances in Experimental Medicine and Biology, vol. 194, pp. 229-239, 1986.
7. H. F. Lodish, Molecular Cell Biology, W. H. Freeman, New York, NY, USA, 2013.
8. F. J. Giordano, "Oxygen, oxidative stress, hypoxia, and heart failure," The Journal of Clinical Investigation, vol. 115, no. 3, pp. 500-508, 2005.
9. A. D. Hafstad, A. A. Nabeebaccus, and A. M. Shah, "Novel aspects of ROS signalling in heart failure," Basic Research in Cardiology, vol. 108, no. 4, article 359, 2013.
10. R. Karimi, Biomedical & Pharmaceutical Sciences with Patient Care Correlations, Jones & Bartlett Learning, 2014.
11. P. A. Frey and A. D. Hegeman, Enzymatic ReactionMechanisms, Oxford University Press, Oxford, UK, 2007.
12. T. Funabiki, Oxygenases and Model Systems, Kluwer Academic Publishers, Boston,Mass, USA, 1997.
13. M. D. Shoulders and R. T. Raines, "Collagen structure and stability," Annual Review of Biochemistry, vol. 78, pp. 929-958, 2009.
14. S. Lindy, H. Turto, and J. Uitto, "Protocollagen proline hydroxylase activity in rat heart during experimental cardiac hypertrophy," Circulation Research, vol. 30, no. 2, pp. 205-209, 1972.
15. T. N. Seagroves, H. E. Ryan, H. Lu et al. , "Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells," Molecular and Cellular Biology, vol. 21, no. 10, pp. 3436-3444, 2001.
16. B. H. Jiang, F. Agani, A. Passaniti, and G. L. Semenza, "VSRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression," Cancer Research, vol. 57, no. 23, pp. 5328-5335, 1997.
17. P. Yang and E. A. Reece, "Role of HIF-1in maternal hyperglycemia-induced embryonic vasculopathy," American Journal of Obstetrics and Gynecology, vol. 204, no. 4, pp. 332. e1-332. e7, 2011.
18. M. E. Cockman, N. Masson, D. R. Mole et al. , "Hypoxia inducible factor-binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein," The Journal of Biological Chemistry, vol. 275, no. 33, pp. 25733-25741, 2000.
19. T. Kamura, S. Sato, K. Iwai,M. Czyzyk-Krzeska, R. C. Conaway, and J. W. Conaway, "Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 19, pp. 10430-10435, 2000.
20. M. Ohh, C. W. Park,M. Ivan et al. , "Ubiquitination of hypoxiainducible factor requires direct binding to the-domain of the vonHippel-Lindau protein," Nature Cell Biology, vol. 2, no. 7,pp. 423-427, 2000.
21. P. C. Mahon, K. Hirota, and G. L. Semenza, "FIH-1: A novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity," Genes and Development, vol. 15, no. 20, pp. 2675-2686, 2001.
22. K. S. Hewitson, L. A. McNeill, M. V. Riordan et al. , "Hypoxiainducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family," Journal of Biological Chemistry, vol. 277, no. 29, pp. 26351-26355, 2002.
23. D. Lando, D. J. Peet, J. J. Gorman, D. A. Whelan,M. L. Whitelaw, and R. K. Bruick, "FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor," Genes and Development, vol. 16, no. 12, pp. 1466-1471, 2002.
24. C. Brahimi-Horn, N. Mazure, and J. Pouysségur, "Signalling via the hypoxia-inducible factor-1alpha requires multiple posttranslationalmodifications," Cellular Signalling, vol. 17,no. 1, pp. 1-9, 2005.
25. G. L. Semenza, "Targeting HIF-1 for cancer therapy," Nature Reviews Cancer, vol. 3, no. 10, pp. 721-732, 2003.
26. J. E. Ziello, I. S. Jovin, andY. Huang, "Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia," Yale Journal of Biology and Medicine, vol. 80, no. 2, pp. 51-60, 2007.
27. W. Liu, S.-M. Shen, X.-Y. Zhao, and G.-Q. Chen, "Targeted genes and interacting proteins of hypoxia inducible factor-1," International Journal of Biochemistry andMolecular Biology, vol. 3, no. 2, pp. 165-178, 2012.
28. D. Chen,M. Li, J. Luo, andW. Gu, "Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function," The Journal of Biological Chemistry, vol. 278, no. 16, pp. 13595-13598, 2003.
29. D. J. Manalo, A. Rowan, T. Lavoie et al. , "Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1," Blood, vol. 105, no. 2, pp. 659-669, 2005.
30. A. J. Krieg, E. B. Rankin,D. Chan,O. Razorenova, S. Fernandez, and A. J. Giaccia, "Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1enhances hypoxic gene expression and tumor growth," Molecular and Cellular Biology, vol. 30, no. 1, pp. 344-353, 2010.
31. W. Luo, H. Hu, R. Chang et al. , "Pyruvate kinaseM2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1," Cell, vol. 145, no. 5, pp. 732-744, 2011.
32. L. Xie, K. Xiao, E. J. Whalen et al. , "Oxygen-regulated 2-Adrenergic receptor hydroxylation by EGLN3 and ubiquitylation by pVHL," Science Signaling, vol. 2, no. 78, article ra33, 2009.
33. E. P. Cummins, E. Berra, K. M. Comerford et al. , "Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 48, pp. 18154-18159, 2006.
34. J. Fu, K. Menzies, R. S. Freeman, and M. B. Taubman, "EGLN3 prolyl hydroxylase regulates skeletal muscle differentiation and myogenin protein stability," The Journal of Biological Chemistry, vol. 282, no. 17, pp. 12410-12418, 2007.
35. J. L. Balligand, R. A. Kelly, P. A. Marsden, T. W. Smith, and T. Michel, "Control of cardiac muscle cell function by an endogenous nitric oxide signaling system," Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 1, pp. 347-351, 1993.
36. N. Paolocc, U. E. G. Ekelund, T. Isoda et al. , "cGMP-independent inotropic effects of nitric oxide and peroxynitrite donors: Potential role for nitrosylation," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 279, no. 4, pp. H1982-H1988, 2000.
37. V. J. Thannickal and B. L. Fanburg, "Activation of an H2O2-generating NADH oxidase in human lung fibroblasts by transforming growth factor beta1,"The Journal of Biological Chemistry, vol. 270, no. 51, pp. 30334-30338, 1995.
38. S.-L. Lee, W.-W. Wang, G. A. Finlay, and B. L. Fanburg, "Serotonin stimulates mitogen-activated protein kinase activity through the formation of superoxide anion," The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 277, no. 2, pp. L282-L291, 1999.
39. T. H. Cheng, N. L. Shih, S. Y. Chen, D. L. Wang, and J. J. Chen, "Reactive oxygen species modulate endothelin-I-induced c-fos gene expression in cardiomyocytes," Cardiovascular Research, vol. 41, no. 3, pp. 654-662, 1999.
40. V. J. Thannickal and B. L. Fanburg, "Reactive oxygen species in cell signaling," American Journal of Physiology-Lung Cellular andMolecular Physiology, vol. 279, no. 6,pp. L1005-L1028, 2000.
41. N. Suematsu, H. Tsutsui, J. Wen et al. , "Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocyte," Circulation, vol. 107, no. 10, pp. 1418-1423, 2003.
42. N. Rathore, S. John, M. Kale, and D. Bhatnagar, "Lipid peroxidation and antioxidant enzymes in isoproterenol induced oxidative stress in rat tissues," Pharmacological Research, vol. 38, no. 4, pp. 297-303, 1998.
43. I. Rahman, "Oxidative stress, chromatin remodeling and gene transcription in inflammation and chronic lung diseases," Journal of Biochemistry andMolecular Biology, vol. 36, no. 1, pp. 95-109, 2003.
44. M. Nishida, Y. Maruyama, R. Tanaka, K. Kontani, T. Nagao, and H. Kurose, "G(i) and G(o) are target proteins of reactive oxygen species," Nature, vol. 408, no. 6811, pp. 492-495, 2000.
45. M. Conrad, C. Jakupoglu, S. G. Moreno et al. , "Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function,"Molecular and Cellular Biology, vol. 24, no. 21, pp. 9414-9423, 2004.
46. H. C. Yen, T. D. Oberley, S. Vichitbandha, Y.-S. Ho, and D. K. St. Clair, "The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice," The Journal of Clinical Investigation, vol. 98, no. 5, pp. 1253-1260, 1996.
47. E. P. Chen, H. B. Bittner, R. D. Davis, R. J. Folz, and P. van Trigt, "Extracellular superoxide dismutase transgene overexpression preserves postischemic myocardial function in isolated murine hearts," Circulation, vol. 94, no. 9, pp. II412-II417, 1996.
48. M. S. Willis,W. H. D. Townley-Tilson,E. Y. Kang, J. W. Homeister, and C. Patterson, "Sent to destroy: The ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease," Circulation Research, vol. 106, no. 3, pp. 463-478, 2010.
49. K. R. Chaudhary, S. N. Batchu, and J. M. Seubert, "Cytochrome P450 enzymes and the heart," IUBMB Life, vol. 61, no. 10, pp. 954-960, 2009.
50. B. K. Park, "Cytochrome P450 enzymes in the heart," The Lancet, vol. 355, no. 9208, pp. 945-946, 2000.
51. B. N. M. Zordoky and A. O. S. El-Kadi, "Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure," Current Drug Metabolism, vol. 9, no. 2, pp. 122-128, 2008.
52. B. M. Babior, "Phagocytes and oxidative stress," The American Journal of Medicine, vol. 109, no. 1, pp. 33-44, 2000.
53. J. Slezak, N. Tribulova, J. Pristacova et al. , "Hydrogen peroxide changes in ischemic and reperfused heart: cytochemistry and biochemical and X-ray microanalysis," The American Journal of Pathology, vol. 147, no. 3, pp. 772-781, 1995.
54. E. A. Podrez, H. M. Abu-Soud, and S. L. Hazen, "Myeloperoxidase-generated oxidants and atherosclerosis," Free Radical Biology and Medicine, vol. 28, no. 12, pp. 1717-1725, 2000.
55. R. K. Schindhelm, L. P. van der Zwan, T. Teerlink, and P. G. Scheffer, "Myeloperoxidase: A useful biomarker for cardiovascular disease risk stratification?" Clinical Chemistry, vol. 55, no. 8, pp. 1462-1470, 2009.
56. S. J. Nicholls and S. L. Hazen, "Myeloperoxidase and cardiovascular disease," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 6, pp. 1102-1111, 2005.
57. R. Zhang, M.-L. Brennan, Z. Shen et al. , "Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation," The Journal of Biological Chemistry, vol. 277, no. 48, pp. 46116-46122, 2002.
58. R. Zhang, M.-L. Brennan, X. Fu et al. , "Association between myeloperoxidase levels and risk of coronary artery disease," The Journal of the AmericanMedical Association, vol. 286, no. 17, pp. 2136-2142, 2001.
59. T. J. Mocatta, A. P. Pilbrow, V. A. Cameron et al. , "Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction," Journal of the American College of Cardiology, vol. 49, no. 20, pp. 1993-2000, 2007.
60. D. Kutter, P. Devaquet, G. Vanderstocken, J. M. Paulus, V. Marchal, and A. Gothot, "Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit?" Acta Haematologica, vol. 104, no. 1, pp. 10-15, 2000.
61. W. E. Cayley Jr. , F. W. Asselbergs, J.-W. C. Tervaert et al. , "Prognostic value of myeloperoxidase in patients with chest pain,"The New England Journal of Medicine, vol. 350, no. 5, pp. 516-518, 2004.
62. D. Gamenara, Redox Biocatalysis: Fundamentals and Applications, JohnWiley & Sons,Hoboken,NJ, USA, 2013.
63. M. E. Martin, B. R. Byers, M. O. J. Olson, M. L. Salin, J. E. Arceneaux, and C. Tolbert, "A Streptococcus mutans superoxide dismutase that is active with either manganese or iron as a cofactor," Journal of Biological Chemistry, vol. 261, no. 20, pp. 9361-9367, 1986.
64. S. Fetzner, "Oxygenases without requirement for cofactors or metal ions," AppliedMicrobiology and Biotechnology, vol. 60,no. 3, pp. 243-257, 2003.
65. L. Aravind and E. V. Koonin, "The DNA-repair protein AlkB, EGL-9, and leprecan define new families of 2-oxoglutarate-and iron-dependent dioxygenases," Genome Biology, vol. 2, no. 3, Article ID RESEARCH0007, 2001.
66. E. M. Antman, D. DeMets, and J. Loscalzo, "Cyclooxygenase inhibition and cardiovascular risk," Circulation, vol. 112, no. 5, pp. 759-770, 2005.
67. L. Parente and M. Perretti, "Advances in the pathophysiology of constitutive and inducible cyclooxygenases: Two enzymes in the spotlight," Biochemical Pharmacology, vol. 65,no. 2, pp. 153-159, 2003.
68. B. Pitt, C. Penine, and J. T. Willerson, "Cyclooxygenase-2 inhibition and cardiovascular events," Circulation, vol. 106, no. 2,pp. 167-169, 2002.
69. F. Cipollone, C. Prontera, B. Pini et al. , "Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E2-dependent plaque instability," Circulation, vol. 104, no. 8, pp. 921-927, 2001.
70. D. Bulut, S. Liaghat, C. Hanefeld, R. Koll, T. Miebach, and A. Mügge, "Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension," Journal of Hypertension, vol. 21, no. 9, pp. 1663-1667, 2003.
71. M. E. Burleigh, V. R. Babaev, J. A. Oates et al. , "Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice," Circulation, vol. 105, no. 15, pp. 1816-1823, 2002.
72. R. J. Bing and M. Lomnicka, "Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events?" Journal of theAmerican College of Cardiology, vol. 39, no. 3, pp. 521-522, 2002.
73. D. Ehrismann, E. Flashman, D. N. Genn et al. , "Studies on the activity of the hypoxia-inducible-factor hydroxylases using an oxygen consumption assay," Biochemical Journal, vol. 401, no. 1, pp. 227-234, 2007.
74. E. Flashman and C. J. Schofield, "The most versatile of all reactive intermediates?" Nature Chemical Biology, vol. 3, no. 2, pp. 86-87, 2007.
75. I. J. Clifton, M. A. McDonough, D. Ehrismann, N. J. Kershaw, N. Granatino, and C. J. Schofield, "Structural studies on 2-oxoglutarate oxygenases and related double-stranded-helix fold proteins," Journal of Inorganic Biochemistry, vol. 100, no. 4, pp. 644-669, 2006.
76. M. Costas, M. P. Mehn,M. P. Jensen, and L. Que Jr. , "Dioxygen activation at mononuclear nonheme iron active sites: enzymes, models, and intermediate," Chemical Reviews, vol. 104, no. 2, pp. 939-986, 2004.
77. U. Puistola, T. M. Turpeeniemi Hujanen, R. Myllyla, and K. I. Kivirikko, "Studies on the lysyl hydroxylase reaction. II. Inhibition kinetics and the reaction mechanism," Biochimica et Biophysica Acta, vol. 611, no. 1, pp. 51-60, 1980.
78. N. P. Talbot, Q. P. Croft,M. K. Curtis et al. , "Contrasting effects of ascorbate and iron on the pulmonary vascular response to hypoxia in humans," Physiological Reports, vol. 2, no. 12, Article ID e12220, 2014.
79. J. D. Webb,M. L. Coleman, andC. W. Pugh, "Hypoxia, hypoxiainducible factors (HIF), HIF hydroxylases and oxygen sensing," Cellular and Molecular Life Sciences, vol. 66, no. 22, pp. 3539-3554, 2009.
80. C. J. Schofield and P. J. Ratcliffe, "Oxygen sensing by HIF hydroxylases," Nature ReviewsMolecular Cell Biology, vol. 5, no. 5, pp. 343-354, 2004.
81. E. Metzen, U. Berchner-Pfannschmidt, P. Stengel et al. , "Intracellular localisation of human HIF-1hydroxylases: implications for oxygen sensing," Journal of Cell Science, vol. 116, no. 7, pp. 1319-1326, 2003.
82. Y.-I. Tsukada, J. Fang, H. Erdjument-Bromage et al. , "Histone demethylation by a family of JmjC domain-containing proteins," Nature, vol. 439, no. 7078, pp. 811-816, 2006.
83. P. Ø. Falnes, R. F. Johansen, and E. Seeberg, "AlkB-mediated oxidative demethylation reverses DNA damage in Escherichia coli," Nature, vol. 419, no. 6903, pp. 178-182, 2002.
84. M. L. Odegaard, J. W. Joseph, M. V. Jensen et al. , "Themitochondrial 2-oxoglutarate carrier is part of a metabolic pathway that mediates glucose-and glutamine-stimulated insulin secretion," The Journal of Biological Chemistry, vol. 285, no. 22, pp. 16530-16537, 2010.
85. K. A. Wehner, S. Schütz, and P. Sarnow, "OGFOD1, a novel modulator of eukaryotic translation initiation factor 2phosphorylation and the cellular response to stress," Molecular and Cellular Biology, vol. 30, no. 8, pp. 2006-2016, 2010.
86. S. McMahon, M. Charbonneau, S. Grandmont, D. E. Richard, and C. M. Dubois, "Transforming growth factor 1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression," Journal of Biological Chemistry, vol. 281, no. 34, pp. 24171-24181, 2006.
87. Y.-H. Chen, L. M. Comeaux, S. J. Eyles, and M. J. Knapp, "Autohydroxylation of FIH-1: An Fe(II),-ketoglutarate-dependent human hypoxia sensor," Chemical Communications, no. 39, pp. 4768-4770, 2008.
88. A. C. R. Epstein, J. M. Gleadle, L. A. McNeill et al. , "C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation," Cell, vol. 107, no. 1, pp. 43-54, 2001.
89. W. G. Kaelin Jr. , "The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing," Biochemical and Biophysical Research Communications, vol. 338, no. 1, pp. 627-628, 2005.
90. M. Hirsilä, P. Koivunen, V. Günzler, K. I. Kivirikko, and J. Myllyharju, "Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor," The Journal of Biological Chemistry, vol. 278, no. 33, pp. 30772-30780, 2003.
91. E. Berra, E. Benizri, A. Ginouvès, V. Volmat, D. Roux, and J. Pouysségur, "HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1in normoxia," The EMBO Journal, vol. 22, no. 16, pp. 4082-4090, 2003.
92. D. A. Chan, P. D. Sutphin, S.-E. Yen, and A. J. Giaccia, "Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1,"Molecular and Cellular Biology, vol. 25, no. 15, pp. 6415-6426, 2005.
93. C. E. Murry, R. B. Jennings, and K. A. Reimer, "Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium," Circulation, vol. 74, no. 5, pp. 1124-1136, 1986.
94. Z. Cai, H. Zhong, M. Bosch-Marce et al. , "Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1," Cardiovascular Research, vol. 77, no. 3, pp. 463-470, 2008.
95. M. S. Marber, D. S. Latchman, J. M. Walker, and D. M. Yellon, "Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction," Circulation, vol. 88, no. 3, pp. 1264-1272, 1993.
96. D. Tekin, A. D. Dursun, and L. Xi, "Hypoxia inducible factor 1 (HIF-1) and cardioprotection," Acta Pharmacologica Sinica, vol. 31, no. 9, pp. 1085-1094, 2010.
97. D. Faeh, F. Gutzwiller, M. Bopp, and Swiss National Cohort Study G, "Lower mortality from coronary heart disease and stroke at higher altitudes in Switzerland," Circulation, vol. 120, no. 6, pp. 495-501, 2009.
98. M. Hölscher, K. Schäfer, S. Krull et al. , "Unfavourable consequences of chronic cardiacHIF-1alpha stabilization," Cardiovascular Research, vol. 94, no. 1, pp. 77-86, 2012.
99. H. Yan, D.-X. Zhang, X. Shi, Q. Zhang, and Y.-S. Huang, "Activation of the prolyl-hydroxylase oxygen-sensing signal cascade leads to AMPK activation in cardiomyocytes," Journal of Cellular andMolecularMedicine, vol. 16,no. 9, pp. 2049-2059, 2012.
100. G. Wright, J. J. Higgin, R. T. Raines, C. Steenbergen, and E. Murphy, "Activation of the prolyl hydroxylase oxygen-sensor results in induction of GLUT1, heme oxygenase-1, and nitricoxide synthase proteins and confers protection from metabolic inhibition to cardiomyocytes," The Journal of Biological Chemistry, vol. 278, no. 22, pp. 20235-20239, 2003.
101. V. Sridharan, J. Guichard, R. M. Bailey, H. Kasiganesan, C. Beeson, and G. L. Wright, "The prolyl hydroxylase oxygensensing pathway is cytoprotective and allows maintenance of mitochondrial membrane potential during metabolic inhibition," The American Journal of Physiology-Cell Physiology, vol. 292, no. 2, pp. C719-C728, 2007.
102. R. Kopp, I. Bauer, A. Ramalingam, M. Egg, T. Schwerte, and V. Lionetti, "Prolonged Hypoxia Increases Survival Even in Zebrafish (Danio rerio) Showing Cardiac Arrhythmia," PLoS ONE, vol. 9, no. 2,Article ID e89099, 2014.
103. M. J. Lohse, S. Engelhardt, andT. Eschenhagen, "What is the role of-adrenergic signaling in heart failure?" Circulation Research, vol. 93, no. 10, pp. 896-906, 2003.
104. M. E. Cockman, D. E. Lancaster, I. P. Stolze et al. , "Posttranslational hydroxylation of ankyrin repeats in IB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH)," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 40, pp. 14767-14772, 2006.
105. M. L. Coleman, M. A. McDonough, K. S. Hewitson et al. , "Asparaginyl hydroxylation of the notch ankyrin repeat domain by factor inhibiting hypoxia-inducible factor," The Journal of Biological Chemistry, vol. 282, no. 33, pp. 24027-24038, 2007.
106. J. E. Ferguson III, Y. Wu, K. Smith et al. , "ASB4 is a hydroxylation substrate of FIH and promotes vascular differentiation via an oxygen-dependent mechanism," Molecular and Cellular Biology, vol. 27, no. 18, pp. 6407-6419, 2007.
107. M. Huang, P. Nguyen, F. Jia et al. , "Double knockdown of prolyl hydroxylase and factor-inhibiting hypoxia-inducible factor with nonviral minicircle gene therapy enhances stem cell mobilization and angiogenesis after myocardial infarction," Circulation, vol. 124, no. 11, pp. S46-S54, 2011.
108. J. H. So, J. D. Kim, K. W. Yoo et al. , "FIH-1, a novel interactor of mindbomb, functions as an essential anti-angiogenic factor during zebrafish vascular development," PLoS ONE, vol. 9, Article ID e109517, 2014.
109. M. Bode, Y. Wu, X. Pi et al. , "Regulation of ankyrin repeat and suppressor of cytokine signalling box protein 4 expression in the immortalizedmurine endothelial cell linesMS1 and SVR: A role for tumour necrosis factor alpha and oxygen," Cell Biochemistry and Function, vol. 29, no. 4, pp. 334-341, 2011.
110. A. B. Aurora, D. Biyashev, Y. Mirochnik et al. , "NF-kappaB balances vascular regression and angiogenesis via chromatin remodeling and NFAT displacement," Blood, vol. 116, no. 3, pp. 475-484, 2010.
111. D. Komander, "Mechanism, specificity and structure of the deubiquitinases," in Conjugation and Deconjugation of Ubiquitin Family Modifiers, vol. 54 of Subcellular Biochemistry, pp. 69-87, Springer, NewYork, NY,USA, 2010.
112. C. M. Grozinger and S. L. Schreiber, "Deacetylase enzymes: biological functions and the use of small-molecule inhibitors," Chemistry and Biology, vol. 9, no. 1, pp. 3-16, 2002.
113. A. Giaccia, B. G. Siim, and R. S. Johnson, "HIF-1 as a target for drug development," Nature Reviews Drug Discovery, vol. 2, no. 10, pp. 803-811, 2003.
114. A. Kuschel, P. Simon, and S. Tug, "Functional regulation of HIF-1under normoxia-is there more than post-translational regulation?" Journal of Cellular Physiology, vol. 227, no. 2, pp. 514-524, 2012.
115. T. Isoe, Y. Makino, K. Mizumoto et al. , "High glucose activates HIF-1-mediated signal transduction in glomerular mesangial cells through a carbohydrate response element binding protein," Kidney International, vol. 78, no. 1, pp. 48-59, 2010.
116. S. Rane, M. He, D. Sayed et al. , "Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiacmyocytes," Circulation Research, vol. 104, no. 7, pp. 879-886, 2009.
117. J.-Y. Li,B.-X. Chai,W. Zhang,Y.-Q. Liu, J. B. Ammori, and M. W. Mulholland, "Akyrin repeat and SOCS box containing protein 4 (Asb-4) interacts with GPS1 (CSN1) and inhibits c-Jun NH2-terminal kinase activity," Cellular Signalling, vol. 19, no. 6, pp. 1185-1192, 2007.
118. W. H. D. Townley-Tilson, Y. Wu, J. E. Ferguson III, and C. Patterson, "The ubiquitin ligase ASB4 promotes trophoblast differentiation through the degradation of ID2," PLoS ONE, vol. 9, no. 2, Article ID e89451, 2014.
119. G. Xu, J. S. Paige, and S. R. Jaffrey, "Global analysis of lysine ubiquitination by ubiquitin remnant immunoaffinity profiling," Nature Biotechnology, vol. 28, no. 8, pp. 868-873, 2010.
120. A. Lundby, K. Lage, B. T. Weinert et al. , "Proteomic analysis of lysine acetylation sites in rat tissues reveals organ specificity and subcellular patterns," Cell Reports, vol. 2, no. 2,pp. 419-431, 2012.
121. F.-M. Boisvert, J. Côté, M.-C. Boulanger, and S. Richard, "A proteomic analysis of arginine-methylated protein complexes," Molecular & Cellular Proteomics, vol. 2, no. 12, pp. 1319-1330, 2003.
122. M. Shimizu, T. Igasaki, M. Yamada et al. , "Experimental determination of proline hydroxylation and hydroxyproline arabinogalactosylation motifs in secretory proteins," Plant Journal, vol. 42, no. 6, pp. 877-889, 2005.
123. K. L. Gorres and R. T. Raines, "Prolyl 4-hydroxylase," Critical Reviews in Biochemistry and Molecular Biology, vol. 45, no. 2, pp. 106-124, 2010.
124. F. Mattiroli and T. K. Sixma, "Lysine-targeting specificity in ubiquitin and ubiquitin-like modification pathways," Nature Structural and Molecular Biology, vol. 21, no. 4, pp. 308-316, 2014.
125. Y.-M. Tian, K. K. Yeoh, M. K. Lee et al. , "Differential sensitivity of hypoxia inducible factor hydroxylation sites to hypoxia and hydroxylase inhibitors," Journal of Biological Chemistry, vol. 286, no. 15, pp. 13041-13051, 2011.
126. I. W. Sizer, "The action of tyrosinase on proteins," Federation proceedings, vol. 5, article 96, 1946.
127. L. Xi, M. Taher, C. Yin, F. Salloum, and R. C. Kukreja, "Cobalt chloride induces delayed cardiac preconditioning in mice through selective activation of HIF-1and AP-1 and iNOS signaling," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 287, no. 6, pp. H2369-H2375, 2004.
128. A. Dendorfer, M. Heidbreder, T. Hellwig-Bürgel, O. Jöhren, F. Qadri, and P. Dominiak, "Deferoxamine induces prolonged cardiac preconditioning via accumulation of oxygen radicals," Free Radical Biology and Medicine, vol. 38, no. 1, pp. 117-124, 2005.
129. R. Ockaili, R. Natarajan, F. Salloum et al. , "HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation," American Journal of Physiology-Heart and Circulatory Physiology, vol. 289, no. 2, pp. H542-H548, 2005.
130. T. Eckle, D. Kohler, R. Lehmann, K. C. E. Kasmi, and H. K. Eltzschig, "Hypoxia-inducible factor-1 is central to cardioprotection a new paradigm for ischemic preconditioning," Circulation, vol. 118, no. 2, pp. 166-175, 2008.
131. J. A. Poynter, M. C. Manukyan, Y. Wang et al. , "Systemic pretreatment with dimethyloxalylglycine increases myocardial HIF-1alpha and VEGF production and improves functional recovery after acute ischemia/reperfusion," Surgery, vol. 150, no. 2, pp. 278-283, 2011.
132. J. Duran, V. Götzens, J. Carballo et al. , "The HIF1A C85T single nucleotide polymorphism influences the number of branches of the human coronary tree," Cardiology, vol. 121, no. 3,pp. 156-159, 2012.
133. M. Alidoosti,M. Ghaedi, A. Soleimani et al. , "Study on the role of environmental parameters and HIF-1A gene polymorphism in coronary collateral formation among patients with ischemic heart disease," Clinical Biochemistry, vol. 44, no. 17-18, pp. 1421-1424, 2011.
134. E. G. Kilian, S. Sadoni, C. Vicol et al. , "Myocardial transfection of hypoxia inducible factor-1via an adenoviral vector during coronary artery bypass grafting-a multicenter phase I and safety study," Circulation Journal, vol. 74, no. 5, pp. 916-924, 2010.
135. W. M. Bernhardt, M. S. Wiesener, P. Scigalla et al. , "Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD," Journal of the American Society of Nephrology, vol. 21, no. 12, pp. 2151-2156, 2010.
136. A. Besarab, D. T. M. Chan, S. L. Dua et al. , "Hypoxia inducing factor prolyl hydroxylase inhibitor FG-4592 corrects anemia in peritoneal dialysis," Journal of the American Society of Nephrology, SA-OR087, 2013.
137. M. A. Besarab, E. N. Chernyavskaya, I. Motylev et al. , "FG-4592, an oral hypoxia-inducible factor prolyl hydroxylase-inhibitor, corrects anemia without iron supplementation in incident dialysis patients," Journal of the American Society of Nephrology, vol. 23, p. 428A, 2012.